Ahmed Shelbaya is a faculty member at Columbia’s Mailman School of Public Health, in the Epidemiology department teaching Global Health. He is also the Founder and Strategic coordinator of the NADA Foundation for Safer Egyptian Roads and a Health Outcomes Researcher with leading pharmaceutical companies. Dr. Shelbaya is a trained physician who practiced clinical pediatrics and neo-natal intensive care for nearly 14 years in developing country settings in Egypt and Sub-Saharan Africa, before being involved in public & global health. Ahmed’s public health work involved collaborating and working with Ministries of Health, the World Health Organization in Geneva, the World Food Program, the African Union’s CDC, designing the Global Framework Convention for Tobacco Control, as well as with other international public health and multinational organizations in New York. He has co-authored numerous publications related to Malaria, HIV, Hep C, anti-infectives, Oncology and health policy. Dr. Shelbaya holds Medical, MSC and MPH degrees from Cairo University as well from Columbia University.

Selected Publications

“Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapy” Zilberberg M, Micek ST, Kollef MH, Shelbaya A, Shorr AF. Journal of Surgical Infection 2012;13 (6):377-82.

“Clinical and economic burden of hospital onset health care facility acquired clostridium difficile infection in Europe: a systemic literature review” Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Journal of Hospital Infection 2012.

“Risk factors for mixed complicated skin and skin structure infections to help tailor appropriate empiric therapy” Zilberberg M, Micek ST, Kollef M, Shelbaya A, Shorr A. Journal of Surgical Infection 2012.

“Re-hospitalization Rates Among Linezolid Versus Vancomycin Users” Mullins C., Hsu V., Shelbaya A. Perencevich E. American Journal of Pharmacy. 2011.

“Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model” Despiegel N.,Felicitas Kuehne F., Martin M., Shelbaya A. Retrovirology. 2011.

‘Non-adherence to oral linezolid after hospitalization: A retrospective claims analysis of the incidence and consequence of claim reversals” Ball A., Xu Y., Sanchez R., Shelbaya A. Deminski D., Nau D. Clinical Therapeutics 2010.

“Achieving equity through reform of the health sector in Egypt,” published in Global Forum Update on Research for Health, Volume 2, by the Global Forum for Health Research 2005.

‘Modeling the clinical and economic impact of the post treatment protection conferred by Artemisinin combination therapies in the treatment of children with uncomplicated P. Falciparum Malaria”. Abstract at the 6th European Congress on Tropical Medicine and International Health in Verona Italy, 2009.

“The clinical and economic effect of Linezolid across the spectrum of patient care: a multicenter comparative study”. Abstract submitted and accepted to the Society for Healthcare Epidemiology of America (SHEA) 2008.

“Modeling the inpatient and outpatient costs of Methicillin-Resistant staphylococcus aureus (MRSA) complicated skin and soft tissue infections (cSSTI): A comparison of Linezolid, Vancomycin, Daptomycin, and Tigecycline”. Abstract submitted and accepted at the International Society of Pharmaco-economics and outcomes research (ISPOR).

“Linezolid vs. Vancomycin Health and Economic Outcomes: A Retrospective Database Study of 14,505 Infectionrelated Treatment Episodes”. Abstract submitted and accepted to the European Congress of clinical microbiology and Infectious diseases (ECCMID) and manuscript published in Journal Clinical Therapeutics.

Impact of benefit design on health outcomes and health economics. Abstract presented at the Academy of Managed Care Pharmacy (AMCP) & manuscript awaiting acceptance at the Journal of Clinical Therapeutics.